A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Clinical trial NCT06077760 · RECRUITING
Trial details
- NCT number
- NCT06077760
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-06
- Primary completion
- 2030-06-25
- Enrollment
- 868
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.